Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $80.1 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Evkeeza, Libtayo, Inmazeb, Arcalyst, and Zaltrap. The biotechnology company is expected to announce its fiscal third-quarter earnings for 2026 before the market opens on Friday, Oct. 30.
Ahead of the event, analysts expect Regeneron Pharmaceuticals to report a profit of $13.58 per share on a diluted basis, up 41% from $9.63 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
For the full year, analysts expect Regeneron Pharmaceuticals to report EPS of $47.93, up 35% from $35.51 in fiscal 2025. Its EPS is expected to rise 10.4% year over year to $52.91 in fiscal 2027.
REGN stock has outperformed the S&P 500 Index’s ($SPX) 16.2% gains over the past 52 weeks, with shares up 35.9% during this period. Similarly, it outperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 22.2% returns over the same time frame.
REGN’s outperformance has been largely driven by robust commercial momentum across key product lines, led by Dupixent, EYLEA HD, and Libtayo, which propelled the company to record sales highs. Dupixent served as a standout performer, with global sales surging near 38% to a record $6 billion and providing a substantial lift to REGN’s collaboration income. Furthermore, the company strengthened its financial profile by fully repaying the Sanofi (SNY) Development Balance, effectively removing a long-standing profit drag. Concurrently, continuous advancements in its clinical pipeline, highlighted by regulatory review acceptances in the U.S. and Europe for cemdisiran in generalized myasthenia gravis, have reinforced investor confidence in its multi-year growth trajectory.
Analysts’ consensus opinion on REGN stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 29 analysts covering the stock, 18 advise a “Strong Buy” rating, two suggest a “Moderate Buy,” and nine give a “Hold.” REGN’s average analyst price target is $862.21, indicating a potential upside of 10.8% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.